Last reviewed · How we verify

IV lignocaine bolus and infusion

University of Auckland, New Zealand · FDA-approved active Small molecule

Lignocaine (lidocaine) is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Lignocaine (lidocaine) is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Acute ventricular arrhythmias (particularly ventricular ectopy and ventricular tachycardia), Local anesthesia (infiltration, regional, topical).

At a glance

Generic nameIV lignocaine bolus and infusion
Also known asLidocaine
SponsorUniversity of Auckland, New Zealand
Drug classLocal anesthetic; Class IB antiarrhythmic agent
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaCardiovascular; Anesthesia
PhaseFDA-approved

Mechanism of action

Lignocaine reversibly binds to voltage-gated sodium channels on the inner surface of nerve cell membranes, inhibiting sodium influx and preventing depolarization. This suppresses the generation and propagation of action potentials in sensory and motor nerves. When administered intravenously as a bolus and infusion, it has systemic effects including antiarrhythmic properties, particularly useful in acute ventricular arrhythmias.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: